Invivyd (IVVD)
NASDAQ:IVVD
Want to see IVVD full AI Analyst Report?
IVVD Stock Chart & Stats
$1.74
-$0.05(-9.00%)
At close: 4:00 PM EST
$1.74
-$0.05(-9.00%)
Day’s Range― - ―
52-Week Range$0.48 - $3.07
Previous CloseN/A
Volume606.77K
Average Volume (3M)2.72M
Market Cap
$327.01M
Enterprise Value-$24.22M
Total Cash (Recent Filing)$184.15M
Total Debt (Recent Filing)$8.63M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 19, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding294,607,450
10 Day Avg. Volume2,638,468
30 Day Avg. Volume2,718,962
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap-0.07
Enterprise Value/Revenue-0.43
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$10.00Price Target Upside474.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$67.29M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained ~93% gross margins indicate strong unit economics on sold doses, providing durable per-unit profitability as volumes scale. High margin biotech products tolerate R&D/SG&A spend longer, improving the company's path to operating leverage if commercial uptake continues.
Solid Balance Sheet Liquidity & Low LeverageLow debt and a multi-hundred-million cash runway reduce near-term refinancing risk and permit sustained investment in pivotal trials and commercialization. This financial flexibility supports execution of late‑stage programs without immediate capital-market dependence.
Commercial Traction With PEMGARDA GrowthRecurring 22% YoY product revenue growth shows market acceptance among eligible patients and validates sales/distribution channels. Durable commercial momentum for the core franchise strengthens revenue base while supporting future launches and repurposing of PEMGARDA infrastructure.
Bears Say
Negative Operating Cash Flow / Cash BurnPersistent negative operating and free cash flow means the company consumes significant cash to run and grow, requiring continued financing until profitable. Even with improved burn versus 2024, sustained negative cash generation elevates dilution and execution risk over the next 2–6 months.
Large Ongoing Net LossesSubstantial recurring losses demonstrate the business is not yet profitable and dependent on successful product expansion or trial outcomes to shift the P&L. Continued negative earnings impair retained capital and increase the probability of future equity or debt raises.
Regulatory & Trial Outcome UncertaintyMaterial near‑term value hinges on DECLARATION and related regulatory decisions; trial event rates and FDA interpretation can alter approval timing, label scope and market access. This conditionality creates structural binary risk to the commercial roadmap and long‑term revenue trajectory.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.48 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $327.01M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Aug 19, 2026 which is in 74 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on May 14, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.057.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.11.
How many shares outstanding does Invivyd have?
Invivyd has 294,607,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -21.088%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (474.71% Upside)
$10.00 (474.71% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.35%
12-Months-Change
Fundamentals
Return on Equity
-53.48%
Trailing 12-Months
Asset Growth
133.02%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
IVVD Company Deck
IVVD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong commercial momentum (PEMGARDA +22% YoY), advancing pivotal trial progress with encouraging safety signals (IDMC reduced monitoring), confirmed neutralization versus a recent Omicron subvariant, an expanding discovery pipeline, and a robust cash position after an April ATM raise. Near-term challenges include elevated clinical spend and burn during the pivotal, continued uncertainty around regulatory outcomes and efficacy readouts driven by event rates, declining COVID vaccine revenue, and imperfect external surveillance and media traction. On balance, concrete operational and scientific progress and expected high efficacy positioning outweigh the near-term financial and market uncertainties.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(474.71% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.49% Insiders
7.58% Mutual Funds
45.05% Other Institutional Investors
31.57% Public Companies and Individual Investors